Héloïse Ragelle
Biomaterials · 2017
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Biomaterials — 16 citations into it
- Biomedical Engineering — 11 citations into it
- Molecular Biology — 10 citations into it
Whom Héloïse Ragelle trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Héloïse Ragelle's perspective
Ordered by how strongly the researchers Héloïse Ragelle trusts endorse each paper. Same corpus, a different order for every researcher.
- Strategies in the design of nanoparticles for therapeutic applications (Nature reviews. Drug discovery)
- Exploiting lymphatic transport and complement activation in nanoparticle vaccines (Nature Biotechnology)
- Trial Watch: Phase II and Phase III attrition rates 2011–2012 (Nature reviews. Drug discovery)
- Impact of nanotechnology on drug delivery. (ACS Nano)
- Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. (Journal of the National Cancer Institute)
- EPR: Evidence and fallacy. (Journal of Controlled Release)
- Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. (Journal of Clinical Oncology)
- Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile (Science Translational Medicine)
- Dose Escalation Methods in Phase I Cancer Clinical Trials (Journal of the National Cancer Institute)
- Challenges in Development of Nanoparticle-Based Therapeutics (AAPS Journal)